Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the publication of key findings on its proprietary RNA amplification process. The study confirms the Company’s improved RNA amplification techniques enhance the quality of the resultant antigen-specific immune response.